Senior Research Associate/Associate Scientist

IGM Biosciences is seeking a Senior Research Associate/Associate Scientist with a background in immunological, biochemical, and protein chemistry techniques to join our rapidly growing team. In this position, you will support the Discovery Biology group primarily in protein characterization (SDS-PAGE, ELISA, western blots, Endotoxin assays, etc.) and functional assays in cell-based systems (Luminescent or flow cytometry based assays).

Qualifications:

  • Master’s degree in biological sciences or related field, or Bachelor’s degree (BS) with 2 years’ experience, preferably in a startup biotech environment.
  • Experience with cell-based assays particularly using flow cytometry.
  • Knowledge of basic computer programs routinely used in a lab such as MS Word, Powerpoint, Excel, GraphPad, etc. Must be able to quickly learn and master new instrument software and programs.
  • Excellent organization, interpersonal, and communication skills.
    Being a team player and respectful of others is a must.
  • 5 years of combined research experience in either academia or industry, with a strong interest in multidisciplinary approaches to molecular biology, chemistry, and immunology research.
  • Experience with mammalian cell culture and micro-titer plate based readouts for cell proliferation and/or killing.
  • Experience with multi-color flow cytometry assays and flowjo software.
  • Experience with protein characterization assays (SDS-PAGE, ELISA, western blots, Endotoxin assays, etc).
  • Experience in maintaining thorough lab records, and adhering to health and safety regulations.
  • Able to thrive in a fast-paced, start-up environment.

IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status. All qualified applicants will receive consideration for employment.

Apply to this position

IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development

Pioneer in Cancer Immunotherapy Research and Clinical Lead for Kite/Gilead ZUMA-5 Program, Dr. Godfrey Joins Chief Medical Officer, Daniel S. Chen, M.D., Ph.D., to Build IGM’s Clinical Development Function

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Wayne Godfrey, M.D. to the newly created position of Vice President, Clinical Development.

Dr. Godfrey will help lead global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. He joins IGM with more than 25 years of experience in cancer immunology and immunotherapy research and development, most recently with Kite/Gilead, where he led the CAR-T CD19-directed pivotal Phase II study, ZUMA-5.

“Wayne has been a pioneer in the field of immuno-oncology, including leading the team that first identified human OX40 and OX40-Ligand with Dr. Edgar G. Engleman at Stanford, and he played an important role in the identification, culture, and characterization of human T regulatory cells at the University of Minnesota, in collaboration with Dr. Bruce R. Blazar. Wayne was an inventor on some of the seminal patents licensed in these fields, and I am honored to have the opportunity to work directly with him,” said Daniel S. Chen, Chief Medical Officer of IGM Biosciences. Dr. Chen continued, “Wayne’s scientific immuno-oncology and clinical hematology experience, combined with his proven leadership abilities as past Chief Medical Officer at Bavarian-Nordic Immunotherapeutics and Etubics, provides IGM with valuable new expertise and know-how as we build IGM’s clinical development capabilities.”

“Wayne’s experience with CAR-T approaches to lymphoma and diverse approaches to cancer immunotherapy in solid tumors will provide strong support for the development of our industry-leading IgM technology platform,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.

Dr. Godfrey commented: “I’m fascinated by IGM’s innovative and proprietary engineering approach to bispecific antibodies, which offers many new avenues for creating the next generation of therapeutics for immuno-oncology and beyond. The ability to target cancer antigens that elude IgG-based therapeutics and the framework for adding multiple additional binding domains and payloads are very compelling. Importantly, the ability of multivalent IgM antibodies to powerfully stimulate signaling receptors may also enable us to realize the true potential of OX40 and other TNFr family members as immuno-oncology targets. I’m very excited to have the opportunity to study and develop the potential of IGM’s technology in the clinic.”

Dr. Godfrey conducted research and studied clinical immunology at Stanford, and then went on to run his own lab as a faculty member in Hematology, Oncology and Transplantation at the University of Minnesota and developed and patented methods to purify and culture T regulatory cells. His biotech and pharma experience has included work on antigen presenting cell vaccines, TLR agonists, and viral-prime boost vaccines in both research and global clinical development roles. Subsequently, he also served as the medical lead for multiple clinical studies of Idelalisib in lymphoma (Phase 1-4) and contributed to the filing and FDA approval of Zydelig® at Gilead Sciences. After working on CEA and HER2 targeted adenoviral cancer vaccines at Etubics/Nantcell, he most recently was the clinical development lead for anti-CD19 directed CAR-T cell studies in follicular lymphoma at Kite/Gilead.

Dr. Godfrey has co-authored multiple clinical and scientific publications, including “Identification of a human OX40 ligand, a costimulatory of CD4+ T cells with homology to tumor necrosis factor,” and “PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma,” published in The New England Journal of Medicine. He is also an inventor or co-inventor on multiple patents, including “Regulatory T cells (CD4+CD25+) and their use in immunotherapy.” Dr. Godfrey earned an M.D. from Washington University and completed his internal medicine residency and Clinical Immunology, Hematology and Bone Marrow Transplantation Fellowships at Stanford University.

Dr. Chen and Dr. Godfrey will be responsible for global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. Dr. Chen joined IGM with more than 20 years of experience in cancer immunotherapy research and development, most recently as Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:

Argot Partners
David Pitts

IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors

Dr. Hambleton Brings More Than 25 Years of Industry and Academic Experience

MOUNTAIN VIEW, Calif., Aug. 15, 2018 – IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Julie Hambleton, M.D., to its Board of Directors. Dr. Hambleton has more than 25 years of academic and industry experience, including 15 years as a leader in preclinical and clinical development at Bristol-Myers Squibb, Five Prime Therapeutics, Clovis Oncology and Genentech. Currently Senior Vice President, Chief Medical Officer and Head of Development at IDEAYA Biosciences, Dr. Hambleton has broad experience across all stages of drug development and was a leader in the successful development of Avastin® and Rubraca®.

“Julie has been at the forefront of some of the most significant advances in oncology/immuno-oncology and hematology, serving as a highly respected medical director and clinical development leader for early-stage companies as well as for some of the most recognized biotechnology and pharmaceutical companies involved in cancer research today,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Her tremendous wealth of experience leading preclinical and clinical operations and strategy, combined with her global regulatory and post-marketing development experience, will be a significant asset, providing IGM with a broad perspective as we advance our pipeline of IgM oncology antibodies into the clinic, and we look forward to her leadership and guidance as a member of our Board of Directors.”

“IGM Biosciences is pioneering an entirely new approach to treating cancer with the development of IgM antibodies that have the potential to significantly expand and advance our current oncology treatment options,” said Dr. Hambleton. “Preclinical observations with IGM’s proprietary IgM antibodies suggest that their novel approach to creating high-avidity IgM antibodies may allow for the successful treatment of a broad range of cancer patients for whom traditional IgG antibodies and other drugs have failed. I have had the privilege to work with some of the industry’s most groundbreaking research and development teams, and I am very excited to be joining IGM as a member of its Board as the company advances its technology toward the clinic.”

Dr. Hambleton currently serves as Senior Vice President, Chief Medical Officer and Head of Development for IDEAYA Biosciences, an oncology-focused biotechnology company. Prior to IDEAYA, Dr. Hambleton was Vice President and Head of U.S. Medical Affairs Research and Development at Bristol-Myers Squibb, where she was responsible for U.S. medical affairs for immuno-oncology/oncology, immunoscience, cardiovascular and virology products, managing a team of 350 employees. At Five Prime Therapeutics, she led preclinical and clinical development, most recently as Executive Vice President and Chief Medical Officer, and she was a member of the IPO and follow-on financing teams. She was also Vice President of Clinical Development at Clovis Oncology. Dr. Hambleton began her career in the biotechnology industry in 2003 at Genentech as Medical Director for the Avastin program. While at Genentech, Dr. Hambleton served in positions of increasing responsibility, overseeing exploratory clinical development for the company’s antiangiogenic pipeline, expansion of Avastin’s clinical program to support approval of Avastin for renal-cell carcinoma and glioblastoma, and she was most recently Group Medical Director of Global Clinical Development, BioOncology, leading the global, cross-functional team responsible for successful clinical trial execution and multiple marketing authorization applications for the Avastin Breast/Ovarian-GYN program.

Dr. Hambleton completed her medical and oncology-hematology training at the University of California, San Francisco, where she then served on faculty until 2003. She received a B.S. from Duke University and an M.D. from Case Western Reserve University School of Medicine, and she is an author or co-author of more than 50 scientific publications.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:
Argot Partners
David Pitts
212-600-1902
igmbiosciences@argotpartners.com

IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors

Dr. Daniel Chen, Former Global Head of Cancer Immunotherapy Development at Genentech/Roche and Noted Immuno-Oncology Expert, to Lead Company’s Emerging Clinical Development Initiatives

Dr. William Strohl, Preeminent Leader in Antibody Research and Development, Brings Wealth of Antibody Engineering Experience

MOUNTAIN VIEW, Calif., Aug. 1, 2018 – IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointments of Daniel S. Chen, M.D., Ph.D., to the newly created position of Chief Medical Officer and William Strohl, Ph.D., to its Board of Directors.

Dr. Chen will be responsible for global clinical development of IGM’s emerging pipeline of proprietary IgM antibodies. He joins IGM with more than 20 years of experience in cancer immunotherapy research and development, most recently as Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.

Dr. Strohl is one of the world’s preeminent leaders in novel antibody engineering. He was formerly Vice President and Head, Janssen BioTherapeutics, Janssen R&D, Johnson & Johnson (J&J), where he ran biologics discovery, early development and technology development.

“Dan and Bill are both pioneers in novel antibody development, and they each bring a wealth of experience and knowledge that will help direct and accelerate the progress of our groundbreaking IgM antibody platform and help guide our lead candidates into and through the clinic,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Dan is widely regarded as a global leader in immuno-oncology, and he oversaw some of the most important R&D in oncology over the last decade while at Genentech/Roche, making his decision to join IGM a strong endorsement of the potential of our technology and our emerging pipeline. Bill is widely regarded as a global thought leader in antibody engineering and novel antibody development, and we look forward to his contributions as a member of our Board of Directors.”

Dr. Chen commented: “IGM’s proprietary scientific and technological approach represents an exciting new frontier for the development of antibody treatments for cancer and other serious diseases. The company’s IgM antibodies have unique advantages over traditional IgG antibodies in that they offer stronger binding to more difficult and rare targets, as well as superior agonist potency. Preclinical research and models suggest the potential for IgM antibodies to offer dramatically superior efficacy to IgG antibodies in certain clinical indications. As a clinician who has been immersed in the immuno-oncology space through what could be described as its most dramatic period of growth, I see tremendous potential in the translation of IGM technology to the clinic.”

“Engineered IgG antibodies remain the bedrock of therapeutic antibody drugs, yet the structural and functional limitations of IgG antibodies are well established,” said Dr. Strohl. “The possibility that IgM antibody technology may address some of these limitations is extremely exciting, and IgM antibodies have tremendous potential to serve unmet medical needs. IGM Biosciences is the clear global leader in the development of IgM antibodies, and I look forward to working with the Board and management team in advancing this groundbreaking new technology.”

Dr. Chen began his tenure with Genentech/Roche in 2006 and was instrumental in building the company’s cancer immunotherapy segment, most recently serving as Vice President, Global Head of Cancer Immunotherapy Development and Cancer Immunotherapy Franchise Head. While with Genentech/Roche, Dr. Chen focused on the clinical development of anti-angiogenic and immune-modulatory targeted therapies in both early- and late-stage development, as well as the diagnostic tools to aid in their development, and he led development of the anti-PD-L1 antibody drug Tecentriq® from preclinical through post-marketing.

Prior to joining Genentech/Roche, Dr. Chen ran the metastatic melanoma clinic at the Stanford Cancer Center where he studied human anti-cancer immune responses to cancer vaccination and cytokine administration and co-invented and developed an MHC cellular microarray to detect and functionally characterize antigen-specific T-cell states. After joining Genentech, Dr. Chen continued as Adjunct Clinical Faculty and was a treating physician for patients with melanoma at Stanford until 2016. He currently serves as co-chair of the Cancer Research Institute’s Cancer Immunotherapy Consortium and was recently elected to the board of the Society for Immunotherapy of Cancer (SITC). Dr. Chen is a noted immuno-oncology expert and speaker, and he delivered the keynote presentation at the AACR NCI EORTC Annual Conference in 2014 and presented at the U.S. Congressional Briefing on Immuno-Oncology in 2017. He is a reviewer for the scientific journals Nature, Immunity and Clinical Cancer Research, and he has co-authored a number of prominent scientific papers in the field of cancer immunotherapy, including the often-referenced Chen and Mellman manuscripts, “Elements of cancer immunity and the cancer-immune set point” and “Oncology meets immunology: the cancer-immunity cycle.” Dr. Chen received a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in microbiology and immunology and an M.D. from the University of Southern California.

Prior to retiring from J&J in August 2016, Dr. Strohl was Vice President and Head, Janssen BioTherapeutics, Janssen R&D, J&J. Previously, Dr. Strohl was Head of Biologics Research, the discovery arm of Janssen BioTherapeutics.  During his time at J&J, Dr. Strohl was responsible for advancing more than 30 novel antibodies into development.

Before joining J&J, Dr. Strohl was with Merck and Co. from 1997 until 2008. At various points during his tenure at Merck, Dr. Strohl led the company’s biologic drug discovery efforts, was involved in multiple biotechnology company acquisitions and licenses to improve discovery capabilities, established its Microbial Vaccines segment and led its Natural Products Biology group. Prior to his work in industry, Dr. Strohl was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl has authored or co-authored more than 140 scientific publications, including “Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry,” which was published in October 2012. Dr. Strohl is also an inventor or co-inventor on 17 issued patents. Dr. Strohl earned a Ph.D. in microbiology and biochemistry from Louisiana State University.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences, Inc. is a privately held biotechnology company that has been dedicated since 2010 to creating and developing novel IgM antibodies that improve the treatment of cancer and other diseases. IGM Biosciences is focused on developing and utilizing IgM antibodies in those clinical indications where their inherent advantages may provide substantially superior performance, as compared with IgG antibodies. For more information about IGM Biosciences, its technologies or its antibody pipeline, please visit www.igmbio.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. IGM Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:
Argot Partners
David Pitts
212-600-1902
igmbiosciences@argotpartners.com

Senior Research Associate, Upstream Process Sciences

IGM Biosciences is hiring a Senior Research Associate in our Upstream Process Sciences group to join our rapidly growing team.  In this position you will support the development of novel antibody products by helping to create upstream processes producing these therapeutic antibodies. You will maintain and expand cells, support the upstream PD lab, and set up and execute antibody production runs at scale up to 25 liters, or larger if needed.

Responsibilities:

  • Maintain and passage CHO expression cell lines.
  • Transfect plasmids into expression cells for transient production.
  • Select and expand expression cell lines for both stable and transient production.
  • Maintain upstream development lab.
  • Determine expression titer by ELISA and other techniques.
  • Document results in laboratory notebooks.
  • Research literature to identify alternative methodologies and solve scientific problems, establish and qualify assays.
  • Prepare technical reports, summaries, and detailed protocols.
  • Share data with management and team members.

Qualifications:

  • BS/BA or higher degree in a biology-related discipline.
  • 3-5 years of experience working with mammalian cell culture and bioreactor/wave systems.
  • Proficiency using Microsoft Office.
  • Aseptic technique.
  • Able to multitask.
  • Able to thrive in a fast-paced, start-up environment.

This job involves working under BSL-2 conditions.

 
IGM is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status.  All qualified applicants will receive consideration for employment.

 
 
Apply to this position